Innovation UBC | October 14, 2025
Through this new collaboration, Alloy will share its expertise and drug discovery technologies to support UBC’s efforts to develop antibody therapies for infectious disease targets. Working directly with UBC’s Pathogen Response Optimization by GENeratIng ThErapeutics Rationally (PROGENITER) program led by Dr. Sriram Subramaniam, Professor and Gobind Khorana Canada Excellence Research Chair, the partnership will combine UBC’s cryo-EM capabilities with Alloy’s antibody discovery platforms to accelerate the development of new therapeutics for pandemic preparedness.
As part of the government of Canada’s commitment to accelerating the development and manufacturing of lifesaving medicines for B.C. and Canada, PROGENITER is part of Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH), one of five national research hubs ensuring Canada is better prepared for present and potential future pandemic threats.